Researchers have conducted one of the first studies to examine the effectiveness of nirmatrelvir-ritonavir (Paxlovid) in non-hospitalized patients during an omicron period of the COVID-19 pandemic that includes BA.4 and BA.5 ...
Feb 10, 2023
2
84
Researchers from Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania found that one in five newborn babies may not have measles antibodies passed down from their ...
Feb 3, 2023
2
90
High levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months. Omicron infection generates durable mucosal antibodies, reducing the risk of re-infection. These are the ...
Jan 16, 2023
0
37
World-first immunizations providing protection against deadly respiratory syncytial virus (RSV) could be just months away thanks to global research efforts spanning multiple decades.
Aug 23, 2022
0
173
Nearly half of cancers worldwide can be traced back to a known risk factor, primarily tobacco or alcohol, a huge global study found on Friday, which said that behavioral changes can help reduce the threat of disease.
Aug 19, 2022
0
371
New research being presented at this year's European Congress on Obesity (ECO) in Maastricht, Netherlands (4-7 May), suggests secondary school pupils across the West Midlands region of the UK are not eating a healthy, sustainable ...
May 4, 2022
0
57
The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not reach its primary goal of improving disease-free survival (DFS) rates for patients with HER2 ...
Jan 21, 2022
0
15
Diagnostics have proven to be crucial to the COVID-19 pandemic response.
Dec 21, 2021
0
19
Researchers at Karolinska Institutet in Sweden recently reported that magnetic resonance imaging (MRI) could reduce overdiagnoses and thereby improve prostate cancer screening. Now, the same research group has published a ...
Aug 13, 2021
0
288
Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...
Jun 18, 2021
0
3
